Polycythemia Vera - Epidemiology Forecast - 2036
Description
Polycythemia Vera Insights and Trends
In the 7MM, the total prevalent population of polycythemia vera is expected to rise from ~283,700 (2025) to 328,200 (2036) at a CAGR of 1.3%, owing to improved diagnostics (JAK2 mutation testing), growing aging population (commonly diagnosed in individuals over 60), increased awareness, longer survival (increase the number of patients living with the condition), etc.
The United States contributed to the highest prevalent population of polycythemia Vera of the 7MM in 2025.
Most Polycythemia Vera patients are symptomatic, with approximately ~91,000 patients with JAK2 mutation in the United States in 2025.
Polycythemia Vera typically develops gradually and may remain asymptomatic for years, with many cases detected incidentally during routine blood tests. Around 40% of polycythemia Vera cases were declared to be asymptomatic.
Polycythemia Vera is associated with mutations in the JAK2 gene, although other mutations may play a role as well. Approximately 96% of patients who have polycythemia Vera have a mutation of the JAK2 gene.
The high rate of late-stage diagnosis in polycythemia Vera underscores a significant unmet need for earlier detection, enhanced monitoring of high-risk populations, and stage-shifting strategies to improve patient survival and long-term outcomes.
Polycythemia Vera Epidemiology forecast (7MM)
2025 Polycythemia Vera Patient pool: ~283,700
2036 Projected Polycythemia Vera Patient pool: ~328,200
Polycythemia Vera Growth Rate (2026–2036): 1.3% CAGR
DelveInsight's ‘Polycythemia Vera (PV)– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Polycythemia Vera Understanding and Diagnosis Algorithm
Polycythemia Vera Overview and Diagnosis
Polycythemia Vera is a rare condition characterized by the progressively increased number of red blood cells in the bloodstream, white blood cells (WBC), and platelets also increase in number in the affected people. Polycythemia Vera is the most common myeloproliferative neoplasm (MPN). Out of all the MPNs, Polycythemia Vera is the most common and the only one in which there is an increase in RBC production. Polycythemia Vera usually occurs at an elderly age, and patients are at a higher risk than the usual percentage, as they are more prone to risks and other comorbidities.
Polycythemia Vera Diagnosis
The diagnosis of Polycythemia Vera is based on results from tests assessing elevations in blood counts and the presence of molecular mutations associated with the disease. The initial evaluation should include a focused clinical history, physical examination, hematocrit concentration, and count of RBC, WBC, platelets, serum EPO level, and cytogenetic abnormalities. The patient's journey begins with a referral to a hematologist. However, the current approach to diagnosing these patients is quite similar, as most developing countries establish a patient’s diagnosis journey using WHO criteria, which is based on a composite assessment of clinical and laboratory features, including JAK2 mutation status and serum erythropoietin level. However, when it comes to analyzing the real-world scenario in varying geographies, there are some differences in diagnostic criteria and risk stratification that other organizations in certain European countries have proposed.
For example, even though the WHO classification considers histology useful in distinguishing Polycythemia Vera from other myeloproliferative neoplasms (MPNs), the British Society for Haematology Guideline has also cited several studies that have reported high rates of failure to reach a histological diagnosis in patients with Polycythemia Vera.
Further details are provided in the report.
Polycythemia Vera Epidemiology
Key Findings from Polycythemia Vera Epidemiological Analysis and Forecast
The United States contributed to the largest prevalent population of Polycythemia Vera, acquiring ~55% of the 7MM in 2025. Whereas EU4 and the UK, and Japan accounted for around ~30% and ~15% of the total population share, respectively, in 2025.
The total number of prevalent cases of Polycythemia Vera in the United States was around ~158,500 cases in 2025.
Among the EU4 and the UK, Germany accounted for the largest number of Polycythemia Vera cases based on symptoms, whereas the UK accounted for the lowest number of cases in 2025.
According to DelveInsight estimates, there were around ~63,000 cases of asymptomatic and ~95,000 cases of symptomatic Polycythemia Vera in the United States in 2025. The prevalence is projected to increase during the forecasted period.
In Japan, the age-specific data revealed that the highest number of people affected with Polycythemia Vera was found in the age group of 65-74 years, i.e., ~6,000 cases in 2025, while people who belonged to the age group 0–34 years, i.e., ~800 cases, were the least affected.
In 7MM, approximately ~60% of the patient share is attributed to males, whereas only ~40% of females suffer from Polycythemia Vera.
Scope of the Report
The report covers a segment of an executive summary, a descriptive overview of Polycythemia Vera, explaining its causes, signs and symptoms, pathogenesis, and Patient burden.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the Polycythemia Vera epidemiology, detailed assumptions, and rationale behind the approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Report Insights
Polycythemia Vera patient population forecast
Country-wise epidemiology distribution
Report Key Strengths
Epidemiology-based (Epi-based) bottom-up forecasting
11-year forecast
Patient Burden trends (by geography)
Report Assessment
Epidemiology Segmentation
Current Diagnostic practices
FAQs
Market Insights
What are the patient burden trends of Polycythemia Vera in the seven major markets?
What are the disease risk, burden, and unmet needs of Polycythemia Vera? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Polycythemia Vera?
What is the historical Polycythemia Vera patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of Polycythemia Vera at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalence of Polycythemia Vera during the study period (2022–2036)?
At what CAGR is the population expected to grow across the 7MM during the study period (2022–2036)?
Reasons to Buy
The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Polycythemia Vera market.
Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.
In the 7MM, the total prevalent population of polycythemia vera is expected to rise from ~283,700 (2025) to 328,200 (2036) at a CAGR of 1.3%, owing to improved diagnostics (JAK2 mutation testing), growing aging population (commonly diagnosed in individuals over 60), increased awareness, longer survival (increase the number of patients living with the condition), etc.
The United States contributed to the highest prevalent population of polycythemia Vera of the 7MM in 2025.
Most Polycythemia Vera patients are symptomatic, with approximately ~91,000 patients with JAK2 mutation in the United States in 2025.
Polycythemia Vera typically develops gradually and may remain asymptomatic for years, with many cases detected incidentally during routine blood tests. Around 40% of polycythemia Vera cases were declared to be asymptomatic.
Polycythemia Vera is associated with mutations in the JAK2 gene, although other mutations may play a role as well. Approximately 96% of patients who have polycythemia Vera have a mutation of the JAK2 gene.
The high rate of late-stage diagnosis in polycythemia Vera underscores a significant unmet need for earlier detection, enhanced monitoring of high-risk populations, and stage-shifting strategies to improve patient survival and long-term outcomes.
Polycythemia Vera Epidemiology forecast (7MM)
2025 Polycythemia Vera Patient pool: ~283,700
2036 Projected Polycythemia Vera Patient pool: ~328,200
Polycythemia Vera Growth Rate (2026–2036): 1.3% CAGR
DelveInsight's ‘Polycythemia Vera (PV)– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Polycythemia Vera Understanding and Diagnosis Algorithm
Polycythemia Vera Overview and Diagnosis
Polycythemia Vera is a rare condition characterized by the progressively increased number of red blood cells in the bloodstream, white blood cells (WBC), and platelets also increase in number in the affected people. Polycythemia Vera is the most common myeloproliferative neoplasm (MPN). Out of all the MPNs, Polycythemia Vera is the most common and the only one in which there is an increase in RBC production. Polycythemia Vera usually occurs at an elderly age, and patients are at a higher risk than the usual percentage, as they are more prone to risks and other comorbidities.
Polycythemia Vera Diagnosis
The diagnosis of Polycythemia Vera is based on results from tests assessing elevations in blood counts and the presence of molecular mutations associated with the disease. The initial evaluation should include a focused clinical history, physical examination, hematocrit concentration, and count of RBC, WBC, platelets, serum EPO level, and cytogenetic abnormalities. The patient's journey begins with a referral to a hematologist. However, the current approach to diagnosing these patients is quite similar, as most developing countries establish a patient’s diagnosis journey using WHO criteria, which is based on a composite assessment of clinical and laboratory features, including JAK2 mutation status and serum erythropoietin level. However, when it comes to analyzing the real-world scenario in varying geographies, there are some differences in diagnostic criteria and risk stratification that other organizations in certain European countries have proposed.
For example, even though the WHO classification considers histology useful in distinguishing Polycythemia Vera from other myeloproliferative neoplasms (MPNs), the British Society for Haematology Guideline has also cited several studies that have reported high rates of failure to reach a histological diagnosis in patients with Polycythemia Vera.
Further details are provided in the report.
Polycythemia Vera Epidemiology
Key Findings from Polycythemia Vera Epidemiological Analysis and Forecast
The United States contributed to the largest prevalent population of Polycythemia Vera, acquiring ~55% of the 7MM in 2025. Whereas EU4 and the UK, and Japan accounted for around ~30% and ~15% of the total population share, respectively, in 2025.
The total number of prevalent cases of Polycythemia Vera in the United States was around ~158,500 cases in 2025.
Among the EU4 and the UK, Germany accounted for the largest number of Polycythemia Vera cases based on symptoms, whereas the UK accounted for the lowest number of cases in 2025.
According to DelveInsight estimates, there were around ~63,000 cases of asymptomatic and ~95,000 cases of symptomatic Polycythemia Vera in the United States in 2025. The prevalence is projected to increase during the forecasted period.
In Japan, the age-specific data revealed that the highest number of people affected with Polycythemia Vera was found in the age group of 65-74 years, i.e., ~6,000 cases in 2025, while people who belonged to the age group 0–34 years, i.e., ~800 cases, were the least affected.
In 7MM, approximately ~60% of the patient share is attributed to males, whereas only ~40% of females suffer from Polycythemia Vera.
Scope of the Report
The report covers a segment of an executive summary, a descriptive overview of Polycythemia Vera, explaining its causes, signs and symptoms, pathogenesis, and Patient burden.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the Polycythemia Vera epidemiology, detailed assumptions, and rationale behind the approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Report Insights
Polycythemia Vera patient population forecast
Country-wise epidemiology distribution
Report Key Strengths
Epidemiology-based (Epi-based) bottom-up forecasting
11-year forecast
Patient Burden trends (by geography)
Report Assessment
Epidemiology Segmentation
Current Diagnostic practices
FAQs
Market Insights
What are the patient burden trends of Polycythemia Vera in the seven major markets?
What are the disease risk, burden, and unmet needs of Polycythemia Vera? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Polycythemia Vera?
What is the historical Polycythemia Vera patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of Polycythemia Vera at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalence of Polycythemia Vera during the study period (2022–2036)?
At what CAGR is the population expected to grow across the 7MM during the study period (2022–2036)?
Reasons to Buy
The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Polycythemia Vera market.
Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.
Table of Contents
128 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Epidemiology Forecast Methodology
- 5. Polycythemia Vera Epidemiology Overview at a Glance
- 5.1. Patient Share of Polycythemia Vera (%) in the 7MM in 2025
- 5.2. Patient Share of Polycythemia Vera (%) in the 7MM in 2036
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Polycythemia Vera: A Type of Myeloproliferative Neoplasm
- 6.3. Signs and Symptoms of Polycythemia Vera
- 6.4. Causes of Polycythemia Vera
- 6.5. Complications due to Polycythemia Vera
- 6.6. Pathophysiology of Polycythemia Vera
- 6.7. Diagnosis of Polycythemia Vera
- 6.7.1. Diagnostic Algorithm of Polycythemia Vera
- 6.8. Diagnostic Guidelines
- 6.8.1. British Society for Haematology (BSH) Guidelines for Polycythemia Vera (2018)
- 6.8.2. WHO Diagnostic Guidelines for Polycythemia Vera (2018)
- 7. Epidemiology and Patient Population of Polycythemia Vera
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Prevalent Population of Polycythemia Vera in the 7MM
- 7.4. Prevalent Population of Polycythemia Vera Based on Symptoms in the 7MM
- 7.5. The United States
- 7.5.1. Total Prevalent Population of Polycythemia Vera in the United States
- 7.5.2. Prevalent Population of Polycythemia Vera Based on Symptoms in the United States
- 7.5.3. Gender-specific Prevalence of Polycythemia Vera in the United States
- 7.5.4. Prevalence of Polycythemia Vera by Gene Mutation in the United States
- 7.5.5. Prevalence of Polycythemia Vera Based on Risk in the United States
- 7.5.6. Age-specific Prevalence of Polycythemia Vera in the United States
- 7.6. EU4 and the UK
- 7.6.1. Total Prevalent Population of Polycythemia Vera in EU4 and the UK
- 7.6.2. Prevalent Population of Polycythemia Vera Based on Symptoms in EU4 and the UK
- 7.6.3. Gender-specific Prevalence of Polycythemia Vera in EU4 and the UK
- 7.6.4. Prevalence of Polycythemia Vera by Gene Mutation in EU4 and the UK
- 7.6.5. Prevalence of Polycythemia Vera Based on Risk in EU4 and the UK
- 7.6.6. Age-specific Prevalence of Polycythemia Vera in EU4 and the UK
- 7.7. Japan
- 7.7.1. Total Prevalent Population of Polycythemia Vera in Japan
- 7.7.2. Prevalent Population of Polycythemia Vera Based on Symptoms in Japan
- 7.7.3. Gender-specific Prevalence of Polycythemia Vera in Japan
- 7.7.4. Prevalence of Polycythemia Vera by Gene Mutation in Japan
- 7.7.5. Prevalence of Polycythemia Vera Based on Risk in Japan
- 7.7.6. Age-specific Prevalence of Polycythemia Vera in Japan
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
